Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis
Status:
Terminated
Trial end date:
2019-08-07
Target enrollment:
Participant gender:
Summary
This is a two-part, multi-center, randomized, double-blind, placebo-controlled,
parallel-group study in patients with hip OA. Approximately 70 patients will be enrolled in
Part I and approximately 440 patients will be enrolled in Part II of the study. In each part,
patients will be randomized to one of two treatment groups (1:1) and treated with a single IA
injection of either 32 mg FX006 or normal saline.